|18 February, 2020

MS Pharma announces new Chief Executive Officer

Previously, Kalle was the CEO of Acino International, a successful international branded generic business active in emerging markets, where he oversaw the company's business mainly in the middle east and Africa.

MS Pharma announces new Chief Executive Officer

Amman: MS Pharma has announced the appointment of Mr. Kalle Känd as the new CEO for the group. Kalle joins MS Pharma with 27 years of global and regional experience in the pharmaceutical and generic space, where he has assumed various senior leadership positions at highly successful pharmaceutical companies.

Previously, Kalle was the CEO of Acino International, a successful international branded generic business active in emerging markets, where he oversaw the company’s business mainly in the middle east and Africa.

As the Chief Executive Officer, Kalle will be responsible for driving the company’s ambitious growth plans and expansions inside and outside the MENA region.

On this occasion, Mr. Ghiath Sukhtian, MS Pharma Chairman, expressed proudly “MS Pharma is very excited to have Kalle on board, where he is ideally positioned to take on this new leadership role with us. He has a strong record of commercial and operational leadership and I am confident that he will create significant value for our company, stakeholders and shareholders”.

From his side, Kalle said, “I am very optimistic about my new journey; I strongly believe it is a transformational time to join MS Pharma where we will build on recent successes to lead the company into its next phase of growth”.

-Ends- 

About MS Pharma:

MS Pharma is a leading pharmaceutical company and partner of choice in Europe, the Middle East, Africa and Turkey. The company has over 2700 employees, a presence in 13 countries and actively sells its products in over 70 countries around the world. The company markets a wide range of generic and biotech products in the MENA region and is active in several therapeutic areas, including cardiovascular, CNS, respiratory and Oncology. Through its subsidiary, Genepharm, the company is also engaged in the development, manufacturing and out-licensing of quality generic pharmaceuticals, and among its customers are the world’s leading pharmaceutical companies. MS Pharma is headquartered in Jordan and has R&D and manufacturing facilities in Greece, Algeria, Jordan, Saudi Arabia and Turkey and manufactures several dosage forms including solids, liquids, cytotoxics and sterile injectables.

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases